Global has decades of experience in being the trusted, gold standard intelligence provider to leading pharmaceutical brands, manufacturers, and suppliers, helping them to make faster, more informed decisions
According to the World Health Organization (WHO), breast cancer is the second most common cancer in the world and the most common cancer in women worldwide, accounting for 25% of all incident cases of female cancers.
On September 15, Amylyx Pharmaceuticals announced that its bid to submit a new drug application (NDA) for its amyotrophic lateral sclerosis (ALS) investigational asset AMX0035, using data from the Phase II CENTAUR trial, has been permitted following recent discussions with the FDA.
On July 6, Seelos Therapeutics announced that the first patient has been dosed in the second part of their registrational, double-blind, placebo-controlled study of SLS-002 (intranasal racemic ketamine) for acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD).
At the virtual 2021 annual American Society of Clinical Oncology conference (ASCO 2021) on June 4–8, results from the Phase III RELATIVITY-047 study for Bristol-Myers Squibb’s (BMS) relatlimab were presented.
At the virtual 2021 annual American Society of Clinical Oncology conference (ASCO 2021) on June 4–8, Johnson & Johnson (J&J) presented updated results from its Phase I/II study CARTITUDE-1 in relapsed/refractory (R/R) multiple myeloma (MM).
Clinical data and industry partnerships have fueled a shift in perception of the microbiome-based therapeutic market from nascent to developing, with GlobalData forecasting the market to be worth $1.554B in 2026.
The Oxford-led Phase II Com-COV trial is investigating immune responses in patients who have been given heterologous prime-boost vaccine schedules using AstraZeneca’s Vaxzevria (ChAdOx1 nCov-19) and Pfizer’s Comirnaty (BNT162b2) COVID-19 vaccines.